Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Aileron Presents Proof-of-Concept Clinical Data for ALRN-6924 in Late-Breaking Presentation at EORTC-NCI-AACR Symposium
Transforming the Experience of Chemotherapy for Patients
Learn More
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
October 24, 2020
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
October 20, 2020
Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
October 12, 2020
Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
More News
